IPO Journey
Conexeu Sciences Inc.
IPO Date: May 11, 2026 · 8 filings tracked
Final Offer Terms
Ticker
CNXU
Exchange
Nasdaq Capital Market
Shares Offered
9,481,123
Expected Listing
May 21, 2026
Filing Timeline
1
S-1
November 28, 2025
- Developing '10 Minute Tissue™', a proprietary collagen-based scaffold for tissue repair.
- Dual-market potential targeting both high-demand wound care and regenerative aesthetics.
2
S-1/A
February 3, 2026
- Pioneering regenerative medicine with CXU™, a proprietary collagen-based liquid scaffold.
- Potential for dual-market application in both wound healing and aesthetic soft tissue filling.
Changes from previous filing
- ▸ Ticker symbol: CNXU
- ▸ Exchange: Nasdaq Capital Market
- ▸ Expected offer range: $8.0 – $12.0 per share
- ▸ Shares offered: 9,481,123
- ▸ Estimated proceeds: $75M
3
S-1/A
March 5, 2026
- Innovative '10-minute tissue' regenerative medicine technology
- Direct listing on Nasdaq under ticker CNXU
Changes from previous filing
- ▸ Price range removed
4
S-1/A
March 26, 2026
- Innovative collagen-based 'liquid bandage' technology (CXU™) for self-healing
- Early-stage medical device company with proprietary scaffold technology
5
S-1/A
April 6, 2026
- Innovative collagen-based liquid-to-gel wound healing technology (CXU™)
- Direct listing approach allows for immediate public market access
6
S-1/A
April 10, 2026
- Developing CXU™, a novel collagen-based scaffold for advanced wound healing
- Dual-market potential targeting both medical wound repair and cosmetic injectable fillers
Changes from previous filing
- ▸ Underwriters: H.C. Wainwright & Co., LLC
7
S-1/A
April 17, 2026
- Innovative '10 Minute Tissue™' collagen-based wound healing technology
- Global patent protection secured in U.S., EU, Japan, and Australia until 2036
424B4
Final Pricing
May 11, 2026
- Developing CXU™, a novel collagen-based scaffold for advanced wound healing
- Potential for dual-market application in both medical wound care and cosmetic fillers
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.